Investigation of the Effect of Date Consumption on Hedonic Hunger and Appetite in Adult Individuals With Type 2 Diabetes

Launched by HACETTEPE UNIVERSITY · Feb 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how eating dates might affect hunger and appetite in adults with type 2 diabetes. The researchers want to find out if eating three dates every day can help reduce cravings for food that are driven more by pleasure (called hedonic hunger) and how it impacts certain hormones related to appetite. They will compare two groups: one that eats dates with breakfast and another that does not eat dates at all.

To be eligible for the study, participants need to be between 19 and 50 years old, have a body mass index (BMI) between 25 and 35, and must not be pregnant or breastfeeding. They should not have any other serious health conditions or be on certain medications that could affect appetite. Participants will be required to keep their usual diet and activity levels the same during the trial. Throughout the study, researchers will conduct interviews and collect blood samples to monitor health changes. This could be a great opportunity for those looking to manage their diabetes better while exploring the potential benefits of adding dates to their diet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals diagnosed with Type 2 diabetes aged 19-50 years (excluding menopausal women),
• • Individuals with BMI between 25-35 kg/m2,
• • Individuals with a Nutritional Strength Scale score of 2.5 and above,
• • Individuals who agreed not to start taking new dietary supplements or alternative therapies during the study period,
• • Individuals who agree not to change their current physical activity level and diet.
• Exclusion Criteria:
• • Individuals who do not approve the volunteer consent form,
• • Individuals with a Nutritional Strength Scale score below 2.5,
• • Pregnant or breastfeeding women (or women planning to become pregnant within 3 months)
• • Individuals with dietary energy \<800 kcal/day and \>4000 kcal/day,
• • Individuals with pre-diabetes, type 1 diabetes and gestational diabetes,
• • Individuals with HbA1c \>10
• • Individuals taking antibiotics or hormone replacement therapy History of malignancy (except non-melanoma skin cancer).
• • Individuals with regular consumption of dates before inclusion in the study,
• • Individuals diagnosed with Type 2 diabetes using insulin and oral antidiabetic drugs with thiazolidinedione active substance,
• • Individuals with a history of diabetic ketoacidosis, diabetic coma or precoma within 6 months prior to the date of admission; serious infections, surgery, serious trauma requiring insulin treatment, haemodialysis treatment (including peritoneal haemodialysis), serious liver injury and serious vascular complications (stroke, myocardial infarction and heart failure) requiring hospitalisation,
• • Individuals taking pharmacological agents that have effects on appetite such as psychotropics, antiepileptics, antidepressants, antipsychotics and/or steroids,
• • Individuals diagnosed with eating disorders and/or psychological disorders,
• • Individuals with physical illnesses that affect eating behaviour or appetite, such as uncontrolled hyperthyroidism or hypothyroidism, Cushing's disease, acromegaly, adrenal insufficiency, chronic renal failure (stage 4 or 5), tuberculosis, human immunodeficiency virus (HIV) infection.